NCT04721132View on ClinicalTrials.gov

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 10, 2021

Primary Completion Date

May 31, 2027

Study Completion Date

December 31, 2027

Conditions
Resectable Hepatocellular CarcinomaStage I Hepatocellular Carcinoma AJCC v8Stage IA Hepatocellular Carcinoma AJCC v8Stage IB Hepatocellular Carcinoma AJCC v8Stage II Hepatocellular Carcinoma AJCC v8
Interventions
BIOLOGICAL

Atezolizumab

Given IV

BIOLOGICAL

Bevacizumab

Given IV

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT04721132 - Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | Biotech Hunter | Biotech Hunter